ArticleThoracic cancer2025
Adjuvant Chemotherapy May be Waived for Breast Cancer Nonresponders to Neoadjuvant Chemotherapy: A Population-Based Large Cohort Study.
Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to evaluate the efficacy of adjuvant chemotherapy (AC) in breast cancer patients who did not respond to neoadjuvant chemotherapy (NAC) following surgery.
methodA retrospective analysis was performed using a large, population-based cohort to identify breast cancer patients who underwent radical surgery following NAC without achieving a response. Kaplan-Meier analysis and Cox regression models were employed to assess clinical outcomes and prognostic factors. Propensity score matching (PSM) was applied to compare outcomes between patients receiving AC vs. those who did not, followed by subgroup analyses.
resultsA total of 1866 patients were included, of whom 1030 received postoperative AC. The median follow-up time was 68.0 months. Patients receiving AC had a median overall survival (OS) of 124.0 months, compared to 93.0 months for those not receiving AC. However, multivariate analysis indicated that receiving postoperative AC was not an independent prognostic factor. Furthermore, PSM analysis indicated no improvement in long-term survival for patients receiving postoperative AC compared to those not receiving it. Subgroup analysis further supported these findings, revealing no significant differences in OS between AC and Non-AC cohorts across various subgroups.
conclusionThese findings suggest that breast cancer patients unresponsive to NAC may derive limited benefit from subsequent AC. Therefore, the decision to administer AC should be carefully considered, and alternative therapeutic strategies should be explored for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.